EUVIMEDEUVIMED entdecken
Crossref

Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1

Jessica Shipley iD, James Beharry, Wei Yeh, Nabil Seery, Yi Chao Foong, Darshini Ayton, Pakeeran Siriratnam, Tracie Tan, Heidi Beadnall, Joshua Barton, Francesca Bridge, Robb Wesselingh und 39 weitere

Medical Journal of Australia · 21.04.2025 · 222 (7) · 356-364

DOI: 10.5694/mja2.52578 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Journal of Australia, online erschienen am 09.02.2025. Verfasst von Jessica Shipley und 50 weiteren Autor:innen. Beteiligte Einrichtung: Alfred Health, Melbourne, VIC. Hauptthemen laut MEDLINE: Multiple Sclerosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction Multiple sclerosis (MS) is a chronic inflammatory demyelinating and degenerative disease of the central nervous system. There were 33 335 people with MS in Australia in 2021 and 2917 in New Zealand in 2006 and the prevalence and incidence are increasing with time. Although new treatments have substantially improved outcomes in recent decades, the treatment landscape has become increasingly complex due to the expanding number of disease‐modifying therapies (DMTs) and associated safety considerations. Main recommendations A total of 80 consensus recommendations were developed on the current best‐practice management of MS in Australia and New Zealand. Part 1 of these guidelines outlines the consensus recommendations covering domains including DMT counselling and selection, pre‐DMT assessments, monitoring disease activity on DMT, switching DMT, and discontinuing DMT. The remaining recommendations are outlined in Part 2, encompassing risk mitigation strategies during treatment with DMT, managing DMT in special situations (including pregnancy, postpartum, breastfeeding, active infection including COVID‐19, and malignancy), general lifestyle measures, acute MS relapses, and symptomatic treatments for MS. Changes in management as a result of the guidelines This two‐part position statement provides a practical resource for clinicians on current best‐practice consensus recommendations for managing adults (≥ 18 years old) with MS in the Australian and New Zealand health care settings. It outlines the 14 DMTs currently available through the Australian Pharmaceutical Benefits Scheme and eight through the New Zealand Pharmaceutical Schedule, including the unique efficacy, safety and monitoring considerations of each. Through these guidelines, we aim to support safe, timely and effective management of patients with MS in Australia and New Zealand.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisHumansNew ZealandAustraliaCOVID-19FemalePregnancyAdult

Stichwörter der Autor:innen

Multiple sclerosis

Autor:innen und Institutionen

  • Alfred Health, Melbourne, VIC.
  • Monash University, Melbourne, VIC.
  • Christchurch Hospital, Christchurch, New Zealand.
  • Royal Hobart Hospital, Hobart, TAS.
  • Brain and Mind Centre, University of Sydney, Sydney, NSW.
  • Sunshine Coast University Hospital, Sunshine Coast, QLD.

ORCID-Profile: Jessica Shipley, Benjamin Peter Trewin, Lauren Giles

Zitieren

APA

Shipley, J., Beharry, J., Yeh, W., Seery, N., Foong, Y. C., Ayton, D., Siriratnam, P., Tan, T., Beadnall, H., Barton, J., Bridge, F., Wesselingh, R., Taylor, L., Rath, L., Haartsen, J., Gadi, M., Nesbitt, C., Zhong, M., Cushing, V., …, & MS Interest Group, Australian and New Zealand Association of Neurologists (2025). Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1. Medical Journal of Australia, 222(7), 356-364. https://doi.org/10.5694/mja2.52578

Vancouver

Shipley J, Beharry J, Yeh W, Seery N, Foong YC, Ayton D, et al. Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1. Medical Journal of Australia. 2025;222(7):356-364. doi:10.5694/mja2.52578

BibTeX
@article{Shipley2025,
  author = {Shipley, Jessica and Beharry, James and Yeh, Wei and Seery, Nabil and Foong, Yi Chao and Ayton, Darshini and Siriratnam, Pakeeran and Tan, Tracie and Beadnall, Heidi and Barton, Joshua and Bridge, Francesca and Wesselingh, Robb and Taylor, Lisa and Rath, Louise and Haartsen, Jodi and Gadi, Mohammad and Nesbitt, Cassie and Zhong, Michael and Cushing, Victoria and McKay, Fiona and Morahan, Julia and Trewin, Benjamin Peter and Roos, Izanne and Marriott, Mark and Nguyen, Ai-Lan and Downey, Emma and Crosby, Joanne and Bosco, Julian and Taylor, Jennifer and Giles, Lauren and John, Nevin and Butler, Ernest and van der Walt, Anneke and Butzkueven, Helmut and Blum, Stefan and Simpson, Marion and Slee, Mark and Ramanathan, Sudarshini and Hardy, Todd and Macdonell, Richard A L and Buzzard, Katherine and Mason, Deborah F and Lechner-Scott, Jeannette and Kilpatrick, Trevor J and Kalincik, Tomas and Taylor, Bruce V and Broadley, Simon A and Reddel, Stephen and Johnson, Douglas and Monif, Mastura and MS Interest Group, Australian and New Zealand Association of Neurologists, MS Interest Group, Australian and New Zealand Association of Neurologists},
  title = {Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1},
  journal = {Medical Journal of Australia},
  year = {2025},
  volume = {222},
  number = {7},
  pages = {356--364},
  doi = {10.5694/mja2.52578}
}
Kostenlos starten →